Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to ...

Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...